Metastatic Prostate Cancer
Metastatic Prostate Cancer occurs when prostate cancer spreads beyond the prostate gland to other parts of the body, often leading to symptoms such as bone pain, weight loss, and fatigue.
Oligometastatic Prostate Cancer: Lu-PSMA and Radiotherapy Study
We are investigating whether combining Lu-PSMA with stereotactic radiotherapy improves survival and quality of life for patients with oligometastatic prostate cancer compared to radiotherapy alone.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have prostate cancer?
- Have you had surgery or radiation treatment for your prostate cancer?
- Have you had chemotherapy or radiation therapy in the last 4 weeks?
- Do you have any known brain metastases?
What similar medicines might you know?
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Lu-177 Psma I&t
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Azienda Unita Sanitaria Locale Della Romagna
Nucleare Medicine Department
Cesena, Italy
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Oncology Department
Meldola, Italy
Sponsor: Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.